Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.49 |
| ▸ | FABP7 | O15540 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31517102 | 0.83 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL29065249 | 0.82 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL10110895 | 0.82 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL29456842 | 0.82 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL23918256 | 0.79 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL7809928 | 0.79 | KMT2A (0.52) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL29398623 | 0.79 | FABP5 (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL12128707 | 0.79 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL44676 | 0.79 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL15981181 | 0.79 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534269-B1 | OXIME CONJUGATES AND METHODS FOR THEIR FORMATION AND USE | GEN HOSPITAL CORP (US) | 2013-10-30 | — | — | EP | disclosed |
| US-8361442-B2 | Oxime conjugates and methods for their formation and use | THE GENERAL HOSPITAL CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120027680-A1 | OXIME CONJUGATES AND METHODS FOR THEIR FORMATION AND USE | THE GENERAL HOSPITAL CORPORATION (US) | 2012-02-02 | — | — | US | disclosed |
| US-8030459-B2 | Oxime conjugates and methods for their formation and use | THE GENERAL HOSPITAL CORPORATION (US) | 2011-10-04 | — | — | US | disclosed |
| US-20060058513-A1 | Oxime conjugates and methods for their formation and use | ENERGY, UNITED STATES DEPARTMENT OF | 2006-03-16 | — | — | US | disclosed |
| EP-1534269-A1 | OXIME CONJUGATES AND METHODS FOR THEIR FORMATION AND USE | THE GENERAL HOSPITAL CORPORATION (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004009082-A1 | OXIME CONJUGATES AND METHODS FOR THEIR FORMATION AND USE | THE GENERAL HOSPITAL CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058513-A1 | Oxime conjugates and methods for their formation and use | GNE, OGA, SORD | KMT2A 1993/4885FABP5 1670/4885FABP7 1290/4885 |
| US-20120027680-A1 | OXIME CONJUGATES AND METHODS FOR THEIR FORMATION AND USE | GNE, SORD, OGA | KMT2A 1993/4885FABP5 1696/4885FABP7 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.